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Pathway-Based Approaches for Analysis of Genomewide
Association Studies
Kai Wang, Mingyao Li, and Maja Bucan
Published genomewide association (GWA) studies typically analyze and report single-nucleotide polymorphisms (SNPs)
and their neighboring genes with the strongest evidence of association (the “most-significant SNPs/genes” approach),
while paying little attention to the rest. Borrowing ideas from microarray data analysis, we demonstrate that pathway-
based approaches, which jointly consider multiple contributing factors in the same pathway, might complement the
most-significant SNPs/genes approach and provide additional insights into interpretation of GWA data on complex
diseases.
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Genomewide association (GWA) studies have greater
power to detect genetic variants that confer modest dis-
ease risks than linkage analysis does, even when a large
number of markers is tested across the genome.1 GWA
aims to identify the genetic architecture of complex dis-
eases, which often result from the interplay of multiple
genetic and environmental risk factors.2 However, in stark
contrast to the notion of “multiple factor–complex dis-
eases,” currently, all published GWA studies list only the
20–50 most-significant SNPs and their neighboring genes
(the “most-significant SNPs/genes” approach), while pay-
ing little attention to the rest. Although such a simple
approach has led to the discovery of novel genes for sev-
eral complex diseases, there are certain limitations. First,
genetic variants that confer small disease risks are likely
to be missed in the most-significant SNPs/genes approach
after adjustment for multiple testing. Second, even those
variants that confer a larger effect might not always rank
among the top 20–50 among hundreds of thousands of
markers tested, especially when the sample size is small.3
Although it is common to report the most-significant re-
sults, in many situations, researchers might formally as-
sign weights to the SNPs according to their biological plau-
sibility. For example, it has been proposed to incorporate
information on genomewide linkage,4 prior belief of the
plausibility of positive findings,5 or prior probability of
disease association6 to assign weights to SNPs in GWA
studies. Simulations demonstrated that such weighted
analyses can improve the power of detecting association
when the weights are assigned appropriately. However, in
many cases, prior linkage information is not available or
does not replicate for complex diseases, and the assign-
ment of a priori probability of association is often arbi-
trary. Here, we demonstrate that pathway-based ap-
proaches, which jointly consider multiple variants in
interacting or related genes, might complement the most-
significant SNPs/genes approach for interpreting GWA
data on complex diseases.
Our proposed approach to the analysis of GWA data is
motivated by pathway-based methods of microarray data
analysis. When expression profiles of different physiolog-
ical states are compared, tens or hundreds of genes may
have subtle differences in expression levels. Rather than
focusing on individual genes that have the strongest evi-
dence of differential expression, these pathway-based ap-
proaches typically rank all genes by their significance of
differential expression and then look for whether a par-
ticular group of genes is enriched at one end of the ranked
list more than would be expected by chance.7 Application
of pathway-based approaches in microarray data analysis
often yields biological insights that are otherwise unde-
tectable by focusing only on genes with the strongest evi-
dence of differential expression. For example, when ex-
pression levels of 22,000 genes were compared in a
microarray study of diabetes, no single gene showed a
statistically significant expression difference after adjust-
ment for multiple testing; however, a pathway-based ap-
proach was capable of identifying a set of PGC-1a–
responsive genes that showed a modest but consistent
change in expression levels in muscle samples from sub-
jects with diabetes.8 We propose that pathway-based ap-
proaches can also be applied to GWA studies of complex
diseases, where multiple genes in the same pathway con-
tribute to disease etiology but where common variations
in each of these genes make modest contributions to dis-
ease risk. Rather than focusing on a few SNPs and/or genes
with the strongest evidence of disease association, by con-
sidering multiple contributing factors together, we poten-
tially can improve the power to detect causal pathways
and disease mechanisms.
There are marked differences between microarray ex-
periments that examine expression levels of transcripts
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and GWA studies that examine population frequencies of
genetic variants. A typical gene has only a few transcripts,
and their expression levels are generally correlated, subject
to regulation by alternative splicing and alternative pro-
moters. Therefore, it is generally acceptable practice to
represent the expression value of a gene by the maximum
or median value of all its transcripts and/or probe sets.
However, a typical gene may be represented on a chip with
either a few or several hundred common SNPs, yet only
one or a few of them contribute to disease risk or are in
linkage disequilibrium (LD) with causal variants. There-
fore, it is not immediately clear what the best strategy is
to condense statistics for multiple SNPs within a gene into
a single value for the gene. To apply pathway-based ap-
proaches to GWA data, we take the maximum statistic for
all SNPs near a gene to represent the significance of the
gene and use a permutation-based approach that shuffles
the phenotype labels of cases and controls to adjust for
multiple testing.
To perform pathway-based analysis of GWA data, we
modified a preexisting algorithm, the gene-set enrichment
analysis (GSEA) algorithm.9 The GSEA algorithm was de-
veloped originally for microarray data analysis, and it per-
forms especially well for situations where subtle effects of
many genes contribute to changes in overall gene-ex-
pression patterns. In our modified algorithm, for each SNP
( , where L is the total number of SNPs in aV ip 1,…,Li
GWA study), we calculated its test statistic value, (e.g.,ri
a x2 statistic for a case-control association test or a x2 sta-
tistic for the transmission/disequilibrium test). We next
associated SNP with gene ( , where N is theV G jp 1,…,Ni j
total number of genes represented by all SNPs) if the SNP
is located within the gene or if the gene is the closest gene
to the SNP. SNPs that are 500 kb away from any gene are
not considered, since most enhancers and repressors are
!500 kb away from genes, and most LD blocks are !500
kb. (In very rare cases where one SNP is located within
shared regions of two overlapping genes, we map the SNP
to both genes.) For each gene, we assigned the highest
statistic value among all SNPs mapped to the gene as the
statistic value of the gene. For all N genes that are repre-
sented by SNPs in the GWA study, we sorted their statistic
values from largest to smallest, denoted by . Forr ,…,r(1) (N)
any given gene set S, composed of genes, we then cal-NH
culated a weighted Kolmogorov-Smirnov–like running-
sum statistic10 that reflects the overrepresentation of genes
within the set S at the top of the entire ranked list of genes
in the genome:
pFr F∗(j ) 1
ES(S)pmax  , { }∗ ∗∗ ∗N NNG S,j j G S,j j1jN j jR H
where and p is a parameter that givespN p  Fr F∗∗R (j )G Sj
higher weight to genes with extreme statistic values.
When , this test statistic reduces to a regularpp 0
Kolmogorov-Smirnov statistic, which identifies groups of
genes whose distribution differs from that of a randomrj
gene set.10 The authors of the original GSEA algorithm
recommend using , and we followed this conventionpp 1
here. The enrichment score, , measures the maximumES(S)
deviation of concentration of the statistic values in gene
set S from a set of randomly picked genes in the genome.
Therefore, if the association signal in S is concentrated at
the top of the list, then will be high.ES(S)
The calculation of relies on the maximum statisticES(S)
within each gene. For genes with a larger number of SNPs,
the maximum statistic will be bigger than for genes with
a smaller number of SNPs. To adjust for gene size, we con-
ducted a two-step correction procedure. In the first step,
we permuted the disease labels of all samples, ensuring
the same number of individuals in each phenotype group
for case-control studies; alternatively, the transmitted and
untransmitted alleles can be shuffled. During each per-
mutation (denoted by p), we repeated the calculation of
enrichment score as described above, except that the dis-
ease phenotypes were obtained from permutation. We de-
note the corresponding enrichment score by . TheES(S,p)
purpose of this step is to calculate values for allES(S,p)
gene sets S and all permutations p. In the second step, we
calculated a normalized enrichment score (NES), defined
as
ES(S)mean[ES(S,p)]
,
SD[ES(S,p)]
so that different gene sets are directly comparable with
each other. The original GSEA algorithm uses a simple
approach by dividing a given ES score for a gene set S by
the mean value of , which does not consider theES(S,p)
different variances of permutated ES scores in gene sets
with varying sizes. Our simple two-step correction pro-
cedure effectively adjusts for different sizes of genes and
preserves correlations of SNPs in the same gene.
Statistical significance and adjustment for multiple hy-
pothesis testing were done by the permutation-based pro-
cedure. In the GSEA algorithm, two measures are used to
adjust for multiple-hypothesis testing. A false-discovery
rate (FDR) procedure can be used to control the fraction
of expected false-positive findings to stay below a certain
threshold.11 For a gene set, let denote the normalized∗NES
enrichment score in the observed data. The FDR11 is cal-
culated as
∗% of all (S,p) with NES(S,p)NES
.∗% of observed S with NES(S)NES
Alternatively, a familywise error rate (FWER) procedure
can be used to adjust for multiple-hypothesis testing. The
FWER is a highly conservative correction procedure that
seeks to ensure that the list of reported results does not
include even a single false-positive gene set. The FWER P
value can be calculated as the fraction of all permutations
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Table 1. The Most-Significant Gene Sets or Pathways
in the Fung et al.12 GWA Study of PD Identified
by a Modified GSEA Algorithm
Gene Set or Pathway
Set
Size
Rank of
Most
Significant
Nominal
P FDR
FWER
PSNP Gene
UDP-glycotransferase activity 89 59 41 !.001 .006 .006
O-glycan biosynthesis 23 69 49 !.001 .011 .018
NOTE.—Two pathways (database identifiers: GO accession number
0008194 and KEGG accession number hsa00512) demonstrate statistical
significance after adjustment for multiple testing, but the SNPs and genes
within these pathways cannot be detected by the most-significant SNPs/
genes approach.
whose highest NES score in all gene sets is higher than
the for a given gene set.∗NES
We applied the pathway-based approach to a published
GWA study of Parkinson disease (PD [MIM 168600]), for
which the raw genotype data are publicly accessible from
the Coriell Institute for Medical Research. This study by
Fung et al.12 genotyped 408K SNPs in 267 patients with
PD and 270 neurologically normal controls in their stage
1 design and identified the 26 most-significantly associ-
ated SNPs. We note that the findings from this study are
highly discordant with another GWA study of PD,13 in that
none of the most-significant genes or even their cytoge-
netic positions overlap with each other. The apparent dis-
cordance between two similar GWA studies underscores
the importance of looking beyond the most-significant
SNPs/genes and searching for additional risk factors with
moderate statistical significance. Our analysis of their data
set used 390K SNPs that pass the initial quality-control
threshold (defined as minor-allele frequency 10.05 and
Hardy-Weinberg equilibrium [HWE] P value14 1.001). Us-
ing a recent human genome assembly (National Center
for Biotechnology Information build 36, October 2005)
and gene-structure annotation from the Ensembl database
(version 42, December 2006),15 we associated SNPs with
their closest protein-coding genes within 500 kb. We used
several different resources to construct a database of gene
sets and pathways. We first retrieved 260 annotated path-
ways from the BioCarta database and 190 annotated path-
ways from the KEGG Pathway Database.16 Next, we down-
loaded Gene Ontology (GO) annotation files for human
genes from the GO Web site.17 We processed the GO an-
notation file and constructed 2,077 gene sets on the basis
of GO level 4 annotations in Biological Process and Mo-
lecular Function. In the GO hierarchy, one node may de-
scend from several ancestral nodes by different paths, and
we excluded from our constructed gene sets those GO level
4 nodes that also occur in levels 2 and 3. Genes whose
GO annotations are in level 5 or lower in the hierarchy
are assigned to their ancestral GO annotations in level 4.
To reduce the multiple-testing issue and to avoid testing
overly narrow or broad functional categories, in our anal-
ysis, we tested only gene sets and pathways that contain
at least 20 but at most 200 genes represented by markers
in a given GWA data set.
Because of the extreme computational complexity of
both permutation-based association tests and the modi-
fied GSEA algorithm, we used only 1,000 permutation cy-
cles to adjust for multiple-hypothesis testing. After appli-
cation of our algorithm to the Fung et al. data set,12 we
identified two significantly enriched gene sets or path-
ways, including the uridine-5′-diphosphate (UDP)–glyco-
transferase pathway and the O-glycan biosynthesis path-
way (table 1). These two pathways are compiled from the
GO database and KEGG database, respectively; they are
functionally related and contain 19 overlapping genes.
The finding that two glycan-related gene sets or pathways
rank high in our pathway-based analysis is quite interest-
ing; the relationship between glycobiology and neuro-
degenerative diseases has been postulated and recognized
only in the past few years.18–21 We note that the GALNT3
(MIM 601756) gene shared in these two pathways was
reported to be one of the most-significant genes in another
GWA study of PD,13 although the most-significant SNPs
around GALNT3 in the study by Fung et al.12 have a P
value of .22. These results suggest that our approach iden-
tified a potential disease-susceptibility mechanism for PD
and generated a new hypothesis for future replication
studies and functional studies of genes that rank high in
the most-significant pathways.
We next examined whether the need for permuting the
phenotype labels (disease status) can be eliminated by a
modified gene-based approach. Unlike microarray data
analysis that operates on only tens of thousands of tran-
scripts and dozens of samples, the permutation of phe-
notypes and recalculation of statistic values for half a mil-
lion SNPs and hundreds or thousands of samples in the
GWA analysis is a very computationally expensive process.
We therefore tested the utility of the “preranked” module
in the GSEA algorithm on P values for all SNPs. After test
statistic values from SNPs are assigned to genes, this gene-
based approach shuffles the test statistic values for all
genes, instead of shuffling the phenotype labels, and then
calculates and to adjust for multiple test-ES(S,p) NES(S,p)
ing. Compared with the approach that we proposed
above, this preranked module of GSEA eliminates the need
for phenotype shuffling and the requirement of the use
of raw genotype data, making it potentially attractive in
many cases.
Since the preranked module of GSEA requires the use
of a single P value to represent the significance of each
gene, we tested two alternative approaches to achieve this
goal. The first approach assigns to the gene the most sig-
nificant P value from all SNPs surrounding the gene. This
approach introduces biases, so that larger genes are likely
to have more-significant P values, and enrichment statis-
tics for pathways containing large genes will be inflated.
The second approach applies a Simes method22–24 and
computes a P value from multiple SNPs. For L SNPs ranked
by their P value, , the Simes P value is calculatedp ,…,p(1) (L)
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Table 2. The Most-Significant Gene Sets and Pathways Identified by a Preranked Module
of the GSEA Algorithm for Two GWA Studies of PD and One GWA Study of AMD
Study and Gene Set or Pathways
Set
Size
Rank of
Most
Significant
Nominal
P FDR
FWER
PSNP Gene
Fung et al.12 stage 1 association study of PD:
Glutamate receptor activity 39 109 77 !.0001 .003 .003
O-glycan biosynthesis 23 155 114 !.0001 .002 .003
Ligand-gated ion channel activity 97 207 153 !.0001 .001 .004
Transmembrane receptor protein phosphatase activity 20 147 106 !.0001 .004 .015
GABA receptor activity 23 109 77 !.0001 .010 .048
Maraganore et al.13 tier 1 association study of PD:
Axon guidance 56 44 31 !.0001 .005 .006
CNS development 130 118 86 !.0001 .034 .068
Glutamate receptor activity 35 34 23 .0007 .069 .189
Klein et al.25 association study of AMD:
CFH-related pathway 4 1 1 !.0001 .004 .004
ABC transporters 42 157 111 !.0001 .046 .088
Skeletal muscle fiber development 25 75 51 !.0001 .065 .181
as , where . The Simes method pro-min{p L/i} 1 i L(i)
vides an overall P value for the entire collection of L hy-
potheses, but it is still an overconservative approach that
might lead to loss of power. We applied these two ap-
proaches to the Fung et al. data set12 on PD and to two
additional GWA data sets for which only P values for SNPs
(but not raw genotypes) are available.
Application of the first approach produced biologically
plausible signals on multiple data sets (table 2). When
applied to the Fung et al. data set12 on PD, it identified a
few pathways that reach statistical significance. The top
gene set or pathway (glutamate receptor) is a well-known
PD-susceptibility pathway and has been implicated in PD
therapy.26,27 We next analyzed another GWA study of PD
by Maranganore et al.13 and found that the glutamate
pathway ranks as the third-best pathway. Finally, we also
tested the first approach on a GWA data set25 on age-re-
lated macular degeneration (AMD [MIM 603075]) from
the dbGaP database and found that the most-significant
pathways in this study are the pathway related to com-
plement factor H (CFH [MIM 134370]) and the ATP-bind-
ing cassette (ABC) transporters pathway. Indeed, the as-
sociation between CFH and AMD has been consistently
replicated after the initial publication, and AMD is one of
the most common genetic diseases that have been asso-
ciated with defects in ABC transporters.28 However, after
application of the second approach with the Simes ad-
justment, the enrichment signals disappeared for all three
data sets, indicating a severe loss of power. Therefore, we
caution that pathway-based methods that use an unad-
justed preranked list of genes are biased, and a more pow-
erful solution for condensing P values from multiple SNPs
into a single value is needed.
Our results demonstrate that pathway-based approaches
may incorporate information from markers with moderate
significance levels and may detect novel disease-suscep-
tibility mechanisms in GWA studies. The identified most-
significant pathways may help formulate new hypotheses
or substantiate existing hypotheses, and genes that rank
high in candidate pathways can serve as candidates for
further replication and functional studies.
The current understanding of human gene function is
incomplete, so the curated gene sets and pathways are not
a comprehensive representation of functionally related
gene cohorts in the human genome. One advantage of
our current approach is that we used annotations from
the GO database to supplement our pathway collections.
The GO database contains large amounts of electronic an-
notations based on studies of human orthologs or paralogs
in model organisms, so that we can incorporate compu-
tationally predicted gene sets and pathways in the gene-
enrichment analysis to improve power. Nevertheless, a
large number of genes in the human genome are un-
characterized or poorly characterized, so that there may
not be any pathway information available. Information
on SNPs near these genes will not be incorporated in the
pathway-based approaches, so our approach can comple-
ment but not replace the single-SNP approach.
The modified GSEA algorithm operates on the maxi-
mum statistic among all SNPs both surrounding and
within a gene and then combines the effects of genes
within the same pathway through the Kolmogorov-Smir-
nov–like running-sum statistic on the maximum statistic
of each gene; therefore, it increases the chance of iden-
tifying genetic variants that have a modest contribution
to disease risk. This pathway-based approach is inherently
different from the “best SNPs/genes” approach, which op-
erates on all SNPs in the entire genome and ignores the
“joint effect” for genes in the same pathway. To adjust for
the effect of different gene sizes, we employed a two-step
permutation-based procedure, which preserves the type I
error rate across genes of different sizes. We note that
larger genes might suffer from power loss more than
smaller genes.
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We recognize that the maximum statistic is only one
way to summarize association signals in a gene. When
multiple distinct variants in the gene contribute to the
overall association signal, the maximum statistic may no
longer be the best statistic to capture such information.
As discussed in our description of methodology, there has
not been a widely agreed on and accepted theory for how
to combine test statistics on multiple SNPs into one single
P value. Genes vary greatly in their sizes and their struc-
tures of LD blocks, so any method for combining P values
may work effectively only on some genes but not on oth-
ers. Our own experience shows that, generally, if several
SNPs in the same gene have higher significance levels than
do other SNPs in the same genomic region, they either
are located in the same LD block or are in the same copy-
number variation (CNV) region (in many cases, HWE fil-
tering criteria are not able to exclude CNV regions from
GWA analysis). Therefore, although there are numerous
cases in which rare variants in different parts of the same
gene may lead to the same or a similar disease phenotype,
generally only one or very few LD blocks in a gene will
harbor common causal variants. These observations sup-
port our use of maximum statistics together with a per-
mutation procedure to adjust for gene sizes. However, we
note that once significant pathways are identified, it is
possible to use multimarker methods for testing marker-
marker or even gene-gene interactions within the same
pathway—for example, by the sum statistics for multiple
markers.29
Our current pathway-based approach is dependent on
the collection of SNPs selected for a specific genotyping
assay. Although some commercially available standardized
arrays are constructed using HapMap data to reduce
marker-marker correlation, many SNP arrays are custom-
made on the basis of prior belief of association (e.g., arrays
specifically designed for SNPs that cause coding changes
or SNPs in conserved genomic regions or arrays supple-
mented with dense markers in prior linkage regions). The
bias in coverage may influence the prior likelihood of de-
tecting associated variants for different genes and may
favor some gene sets and pathways over others. For these
reasons, we caution that pathway-based approaches may
work better on marker sets selected on the basis of ge-
nomewide LD structure than on custom-made genotyping
arrays.
Constructed gene sets and pathways may be dependent
on each other or may correlate with each other. Cellular
components and molecules do not work in isolation; in-
stead, pathways overlap, so that many gene sets and path-
ways will unavoidably share the same genes. The overlap
of genes among gene sets and pathways will not affect
their relative ranking of NES values; however, because of
the permutation procedure for multiple-hypothesis ad-
justment, dependent pathways will lead to decreased
power (in terms of both FDR and FWER) when the causal
genes are shared by multiple pathways.
Our modified GSEA algorithm preserves correlation
structures between SNPs when permuting the data and
therefore can potentially increase the power for detecting
association more than can approaches that ignore such
correlation. We note that the pathway-based method does
not take gene-gene correlation into account. Although
this might be a serious issue in microarray data analysis,
it is less of a concern in GWA studies, in which genes in
the same pathway may be dependent on each other only
if they overlap the same LD block or if there are epistatic
interactions between them. In these cases, the contribu-
tion of genes to test statistics may be correlated and may
lead to overestimation of significance of pathways.
In conclusion, our results demonstrate the applicability
of pathway-based approaches to the interpretation and
analysis of GWA data. We hope to encourage the com-
munity to look beyond the tip of the iceberg (the most-
significant SNPs/genes) for GWA analysis of complex dis-
eases. The development of pathway-based approaches that
incorporate and weigh prior biological knowledge, in-
cluding those gleaned from model organisms, will greatly
facilitate the interpretation of GWA data and will lead to
the identification of novel disease-susceptibility genes and
mechanisms.
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